Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
I-Mab (the "Company") (Nasdaq" IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of...
I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and...
-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and...
I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of...
Financial results demonstrate strong fundamentals Twenty key clinical milestones achieved year-to-date, including positive data readouts for...
I-Mab ( "I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and...
I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of...
- New appointments as part of the Company's strategic development plans to accelerate transformation towards commercialization - Dr. Andrew Zhu, an...
I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of...
The partnership brings together the strengths of an innovative global biotech and a domestic leading pharmaceutical company specialized in and...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.